FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * ALTA BIOPHARMA PARTNERS III LP   2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [CARA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) ONE EMBARCADERO CENTER, 37TH FLOOR,  3. Date of Earliest Transaction (Month/Day/Year) 02/05/2014 (Street) SAN FRANCISCO, CA 94111 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/05/2014   C(1)   1,118,675 A $ 0 1,118,675 I See Footnote (2) Common Stock 02/05/2014   C(3)   531,442 A $ 0 1,650,117 I See Footnote (2) Common Stock 02/05/2014   P   103,330 A $ 11 1,753,447 I See Footnote (2) Common Stock 02/05/2014   C(1)   75,129 A $ 0 75,129 I See Footnote (4) Common Stock 02/05/2014   C(3)   35,691 A $ 0 110,820 I See Footnote (4) Common Stock 02/05/2014   P   6,940 A $ 11 117,760 I See Footnote (4) Common Stock 02/05/2014   C(1)   27,568 A $ 0 27,568 I See Footnote (5) Common Stock 02/05/2014   C(3)   13,097 A $ 0 40,665 I See Footnote (5) Common Stock 02/05/2014   P   2,547 A $ 11 43,212 I See Footnote (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series C Preferred Stock	(1)	02/05/2014		C			2,363,654	(1)	(1)	Common Stock	1,118,675	$ 0	0	I	See Footnote (2)
Series C Preferred Stock	(1)	02/05/2014		C			158,741	(1)	(1)	Common Stock	75,129	$ 0	0	I	See Footnote (4)
Series C Preferred Stock	(1)	02/05/2014		C			58,250	(1)	(1)	Common Stock	27,568	$ 0	0	I	See Footnote (5)
Series D Preferred Stock	(3)	02/05/2014		C			1,328,604	(3)	(3)	Common Stock	531,442	$ 0	0	I	See Footnote (2)
Series D Preferred Stock	(3)	02/05/2014		C			89,227	(3)	(3)	Common Stock	35,691	$ 0	0	I	See Footnote (4)
Series D Preferred Stock	(3)	02/05/2014		C			32,742	(3)	(3)	Common Stock	13,097	$ 0	0	I	See Footnote (5)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
ALTA BIOPHARMA PARTNERS III LP ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111		X
ALTA BIOPHARMA MANAGEMENT III LLC C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111		X
ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111		X
ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111		X
CHAMPSI FARAH C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111		X
HURWITZ EDWARD C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111	X	X
PENHOET EDWARD C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111		X

Signatures

/s/Darren DeStefano, Attorney-in-Fact		02/05/2014
**Signature of Reporting Person		Date
Darren DeStefano, Attorney-in-Fact		02/05/2014
**Signature of Reporting Person		Date
Darren DeStefano, Attorney-in-Fact		02/05/2014
**Signature of Reporting Person		Date
Darren DeStefano, Attorney-in-Fact		02/05/2014
**Signature of Reporting Person		Date
Darren DeStefano, Attorney-in-Fact		02/05/2014
**Signature of Reporting Person		Date
Darren DeStefano, Attorney-in-Fact		02/05/2014
**Signature of Reporting Person		Date
Darren DeStefano, Attorney-in-Fact		02/05/2014
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The Series C Preferred Stock held by the reporting persons automatically converted on a 1-for-2.1129 basis into shares of common stock upon the closing of the issuer's initial public offering.
(2)	These shares are held of record by Alta BioPharma Partners III, L.P. ("ABP III"). Alta BioPharma Management III, LLC ("ABM III") is the general partner of ABP III. Edward Hurwitz, a director of the issuer, Farah Champsi and Edward Penhoet are directors of ABM III and may be deemed to share dispositive and voting power over the shares held by ABP III. Each of the reporting persons disclaims beneficial ownership of these securities except to the extent of his, her or its respective pecuniary interest therein.
(3)	The Series D Preferred Stock held by the reporting persons automatically converted on a 1-for-2.5 basis into shares of common stock upon the closing of the issuer's initial public offering.
(4)	These shares are held of record by Alta BioPharma Partners III GmbH & Co. Beteiligungs KG ("GmbH"). ABM III is the managing limited partner of GmbH. Edward Hurwitz, a director of the issuer, Farah Champsi and Edward Penhoet are directors of ABM III and may be deemed to share dispositive and voting power over the shares held by GmbH. Each of the reporting persons disclaims beneficial ownership of these securities except to the extent of his, her or its respective pecuniary interest therein.
(5)	These shares are held of record by Alta Embarcadero BioPharma Partners III, LLC ("Embarcadero"). Edward Hurwitz, a director of the issuer, Farah Champsi and Edward Penhoet are the managers of Embarcadero and may be deemed to share dispositive and voting power over the shares held by Embarcadero. Each of the reporting persons disclaims beneficial ownership of these securities except to the extent of his, her or its respective pecuniary interest therein.
Remarks: Please note that all of these reporting persons are no longer subject to Section 16 Form 4 or Form 5 obligations, with the exception of Edward Hurwitz, who will have an ongoing Section 16 reporting obligation as a director of the issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.